Pharmacogenetics and the concept of individualized medicine (original) (raw)

• Lazarou J, Pomeranz BH, Corey PN . Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200–1205.
  Article CAS Google Scholar
• Dormann H, Neubert A, Criegee-Rieck M, Egger T, Radespiel-Troger M, Azaz-Livshits T et al. Readmissions and adverse drug reactions in internal medicine: the economic impact. J Int Med 2004; 255: 653–663.
  Article CAS Google Scholar
• Zheng CJ, Sun LZ, Han LY, Ji ZL, Chen X, Chen YZ . Drug ADME associated protein data base as a resource for facilitating pharmacogenomics research. Drug Dev Res 2004; 62: 134–142.
  Article CAS Google Scholar
• Lin M, Aquilante C, Johnson JA, Wu R . Sequencing drug response with HapMap. Pharmacogenomics J 2005; 5: 149–156.
  Article CAS Google Scholar
• Stoughton RB, Friend SH . How molecular profiling could revolutionize drug discovery. Nat Rev Drug Discov 2005; 4: 345–350.
  Article CAS Google Scholar
• Phillips KA, Van Bebber SL . Measuring the value of pharmacogenomics. Nat Rev Drug Discov 2005; 4: 500–509.
  Article CAS Google Scholar
• Wilkinson GR . Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211–2221.
  Article CAS Google Scholar
• Shastry BS . Genetic diversity and new therapeutic concepts. J Hum Genet 2005; 50: 321–328.
  Article CAS Google Scholar
• Shastry BS . Role of SNP/haplotype in gene discovery and drug development: an overview. Drug Dev Res 2004; 62: 143–150.
  Article CAS Google Scholar
• Glodstein DB, Tate SK, Sisodiya SM . Pharmacogenetics goes genomic. Nat Rev Genet 2003; 4: 937–947.
  Article Google Scholar
• Szekeres T, Haushofer A . Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation. Pharmacogenomics 2005; 6: 163–168.
  Article CAS Google Scholar
• Hesselink DA, van Gelder T, van Schaik RH . The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 2005; 6: 323–337.
  Article CAS Google Scholar
• Xie H-G, Kim RB, Wood AJJ, Stein CM . Molecular basis of ethnic differences in drug disposition and response. Ann Rev Pharmacol Toxicol 2001; 41: 815–850.
  Article CAS Google Scholar
• de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ . The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 205; 66: 15–27.
  Article Google Scholar
• Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL et al. Prospective dosing of warfarin based on cytochrome P450 2C9 genotype. Thromb Haemost 2005; 93: 700–705.
  Article CAS Google Scholar
• Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D et al. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 2005; 33: 749–753.
  Article CAS Google Scholar
• Totah RA, Rettie AE . Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics and clinical relevance. Clin Pharmacol Ther 2005; 77: 341–352.
  Article CAS Google Scholar
• He P, Court MH, Greenblatt DJ, Von Moltke LL . Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 2005; 77: 373–387.
  Article CAS Google Scholar
• Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A . Mechanism of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 2005; 6: 115–138.
  Article CAS Google Scholar
• Hulot JS, Villard E, Maguy A, Morel V, Mir L, Tostivint I et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 2005; 15: 277–285.
  Article CAS Google Scholar
• Lim AY, Gaffney K, Scott DG . Methotrexate-induced pancytopenia: serious and under reported? Our experience of 25 cases in 5 years. Rheumatology 2005; 44: 1051–1055.
  Article CAS Google Scholar
• Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 2005; 46: 643–647.
  Article CAS Google Scholar
• Wang L, Nguyen TV, McLaughlin RW, Sikkink LA, Ramirez-Alvarado M, Weinshilboum RM . Human thiopurine _S_-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci USA 2005; 102: 9394–9399.
  Article CAS Google Scholar
• Stanulla M, Schaeffeler E, Flohr T, Cario C, Schrauder A, Zimmermann M et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005; 293: 1485–1489.
  Article CAS Google Scholar
• McLeod HL, Krynetski EY, Relling MV, Evans WE . Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 567–572.
  Article CAS Google Scholar
• Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M et al. Comprehensive analysis of thiopurine S-methyltrasnsferase (TPMT) phenotype–genotype correlation in a large population of German–Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14: 407–417.
  Article CAS Google Scholar
• Gearry RB, Barclay ML . Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. Gastroenterol Hepatol 2005; 20: 1149–1157.
  Article CAS Google Scholar
• Etienne MC, Formento JL, Chazal M, Francoual M, Magne N, Formento P et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004; 14: 785–792.
  Article CAS Google Scholar
• Gomes ER, Demoly P . Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5: 309–316.
  Article Google Scholar
• Vadlamani L, Iyenger S . Tumor necrosis factor alpha polymorphism in heart failure/cardiomyopathy. Congest Heart Fail 2004; 10: 289–292.
  Article CAS Google Scholar
• McNamara DM . Pharmacogenetics in heart failure: genomic markers of endothelial and neurohumoral function. Congest Heart Fail 2004; 10: 302–308.
  Article CAS Google Scholar
• Maitland-van der zee AH, Turner ST, Schwartz GL, Chapman AB, Klungel OH, Boerwinkle E . A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide. Pharmacogenet Genomics 2005; 15: 287–293.
  Article CAS Google Scholar
• Liljedahl U, Kahan T, Malmqvist K, Melhus H, Syvanen AC, Lind L, Kurland L . Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. J Hypertens 2005; 22: 2273–2275.
  Google Scholar
• Mellen PB, Herrington DM . Pharmacogenomics of blood pressure response to antihypertensive treatment. J Hypertens 2005; 23: 1311–1325.
  Article CAS Google Scholar
• King D, Etzel JP, Chopra S, Smith J, Cadman PE, Rao F et al. Human response to alpha 2-adrenergic agonist stimulation studied in an isolated vascular bed in vivo: biphasic influence of dose, age, gender and receptor genotype. Clin Pharmacol Ther 2005; 77: 388–403.
  Article CAS Google Scholar
• Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS et al. beta-adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 2005; 77: 127–137.
  Article CAS Google Scholar
• Taylor MR, Bristow MR . The emerging pharmacogenomics of the beta-adrenergic receptors. Congest Heart Fail 2004; 10: 281–288.
  Article CAS Google Scholar
• Tantisira KG, Small Km, Litonjua AA, Weiss ST, Liggett SB . Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet 2005; 14: 1671–1677.
  Article CAS Google Scholar
• Kukreti R, Bhatnagar P, B-Rao C, Gupta S, Madan B, Das C et al. Beta (2)-adrenergic receptor polymorphisms and response to salbutamol among Indian asthmatics. Pharmacogenomics 2005; 6: 399–410.
  Article CAS Google Scholar
• Serrette A, Artioli P, Quartesan R . Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics 2005; 15: 61–67.
  Article Google Scholar
• Sink KM, Holden KF, Yaffe K . Pharmacological treatment of neuropsychiatric symptoms of dementia. JAMA 2005; 293: 596–608.
  Article CAS Google Scholar
• Rybakowsky JK, Suwalska A, Czerski PM, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J . Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacol Rep 2005; 57: 124–127.
  Google Scholar
• Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z . Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 2005; 15: 143–151.
  Article CAS Google Scholar
• Wilffert B, Zaal R, Brouwers JR . Pharmacogenetics as a tool in the therapy of schizophrenia. Pharm World Sci 2005; 27: 20–30.
  Article CAS Google Scholar
• Ferraro TN, Buono RJ . The relationship between pharmacology of antiepileptic drugs and human gene variation: an overview. Epilepsy Behav 2005; 7: 18–36.
  Article Google Scholar
• Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 2005; 102: 5507–5512.
  Article CAS Google Scholar
• Soranzo N, Goldstein DB, Sisodiya SM . The role of common variation in drug transporter genes in refractory epilepsy. Expert Opin Pharmacother 2005; 6: 1305–1312.
  Article CAS Google Scholar
• Linazasoro G . New ideas on the origin of l-Dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci 2005; 26: 391–397.
  Article CAS Google Scholar
• Stamer UM, Bayerer B, Stuber F . Genetics and variability in opioid response. Eur J Pain 2005; 9: 101–104.
  Article CAS Google Scholar
• Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA . Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 2005; 57: 1–26.
  Article CAS Google Scholar
• Gourlay GK . Advances in opioid pharmacology. Support Care Cancer 2005; 13: 153–159.
  Article Google Scholar
• Mogil JS, Ritchie J, Smith SB, Strasburg K, Kaplan L, Wallace MR et al. Melanocortin-1 receptor gene variants affect pain and (micro)-opioid analgesin in mice and humans. J Med Genet 2005; 42: 583–587.
  Article CAS Google Scholar
• Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ et al. UDP Glucuronosyltransferase (UGT) 1A6 pharmacogenetics: identification of polymorphisms in the 5′-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. Pharmacol Exp Ther 2005; 313: 1331–1339.
  Article CAS Google Scholar
• Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: functional impact of the three most common non-synonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). Pharmacol Exp Ther 2005; 313: 1340–1346.
  Article CAS Google Scholar
• Dahl JP, Doyle GA, Oslin DW, Buono RJ, Ferraro TN, Lohoff FW et al. Lack of association between single nucleotide polymorphisms in the corticotrophin releasing hormone receptor 1 (CRHR 1) gene and alcohol dependence. J Psychiatr Res 2005; 39: 475–479.
  Article Google Scholar
• Daar AS, Singer PA . Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nat Rev Genet 2005; 6: 241–246.
  Article CAS Google Scholar
• Rahemtulla T, Bhopal R . Pharmacogenetics and ethnically targeted therapies. BMJ 2005; 330: 1036–1037.
  Article Google Scholar
• Chowbay B, Zhou S, Lee EJ . An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev 2005; 37: 327–378.
  Article CAS Google Scholar
• Mori M, Yamada R, Kobayashi K, Kawaida R, Yamamoto K . Ethnic differences in allele frequency of autoimmune disease-associated SNPs. J Hum Genet 2005; 50: 264–266.
  Article Google Scholar
• Mitchell AA, Chakravarti A, Cutler DJ . On the probability that a novel variant is a disease-causing mutation. Genome Res 2005; 15: 960–966.
  Article CAS Google Scholar
• Kaplan JB, Bennett T . Use of race and ethnicity in biomedical publication. JAMA 2003; 289: 2709–2716.
  Article Google Scholar
• Freudenberg-Hua Y, Freudenberg J, Winantea J, Kluck N, Cichon S, Bruss M et al. Systematic investigation of genetic variability in 111 human genes – implication for studying variable drug response. Pharmacogenomics J 2005; 5: 183–192.
  Article CAS Google Scholar
• Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285–2293.
  Article CAS Google Scholar
• Hall AM, Wilkins MR . Warfarin: a case history in pharmacogenetics. Heart 2005; 9: 563–564.
  Article Google Scholar
• Yu CM, Chan TYK, Critchley JAJH, Woo KS . Factors determining the maintenance dose of warfarin in Chinese patients. Q J Med 1996; 89: 127–135.
  Article CAS Google Scholar
• Yu CM, Chan TY, Tsoi WC, Sanderson JE . Heparin therapy in the Chinese – lower doses are required. Q J Med 1997; 90: 535–543.
  Article CAS Google Scholar
• Taylor AL, Zieshe S, Yancy C, Carson P, D’Agostino R, Ferdinand K et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049–2057.
  Article CAS Google Scholar
• Lindpaintner K . Pharmacogenetics and pharmacogenomics. Methods Mol Med 2005; 108: 235–260.
  CAS PubMed Google Scholar
• Need AC, Motulsky AG, Goldstein GB . Priorities and standards in pharamacogenetic research. Nat Genet 2005; 37: 671–681.
  Article CAS Google Scholar
• Rogausch A, Brockmoller J, Himmel W . Pharmacogenetics in future medical care – implications for patients and physicians. Gresundheitswesen 2005; 67: 257–263.
  Article CAS Google Scholar
• Efferth T, Volm N . Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005; 107: 155–176.
  Article CAS Google Scholar
• Smits KM, Schouten JS, Smits LJ, Stelma FF, Nelemans P, Prins MH . A review on the design and reporting of studies on drug–gene interaction. J Clin Epidemiol 2005; 58: 651–654.
  Article Google Scholar